From May 19th to 21st, the 2026 Future Medical and Pharmaceutical Top 100 Conference will be held in Shanghai, where government, industry, academia, research, medical investment and other sectors will gather to focus on cutting-edge fields such as brain computer interfaces, medical AI, synthetic biology, and jointly explore the future development of China's medical and health industry. The results of the 10th Future Medical Top 100 selection released by the conference show that the total valuation of the 300 listed companies is about 809 billion yuan, and the industry presents a distinct feature of being dominated by the middle and late stages and active by the new generation. China's medical innovation is moving from scale expansion to a new stage of high-quality development and globalization. Frontier technologies continue to break through, and the global technological revolution and industrial transformation are deeply intertwined. Frontier technologies such as artificial intelligence, synthetic biology, and brain computer interfaces are reshaping the healthcare landscape. No matter how technology advances, the foundation of healthcare lies in clinical practice, health, and people's livelihoods. "At the main forum, Xu Shuqiang, President of the China Hospital Development Research Institute and a professor at Shanghai Jiao Tong University, believed that the focus of all innovation must be to solve patients' illnesses, improve medical accessibility and fairness. Focusing on cultivating new quality productivity, synthetic biology has become a new engine driving the upgrading of the big health industry. Deng Zixin, Chair Professor and Honorary Dean of the School of Life Sciences and Technology at Shanghai Jiao Tong University, and Director of the National Key Laboratory of Microbial Metabolism, proposed that synthetic biology can achieve targeted design and heterologous synthesis of natural products, break through resource limitations, and solve the environmental pollution problem in drug production. At present, the team's gene editing and nucleic acid detection technology based on sulfur modification has formed an independent intellectual property patent pool, which is promoting the transformation of domestic biomanufacturing from imitation to original innovation. Nowadays, China's brain computer interface field has entered the world's top tier with its full chain independent innovation strength. "In the future, the development of brain computer interface will focus on the real-time feedback optimization stimulation of the brain, multi target collaborative therapy, and the combined application of invasive and non-invasive technologies." Pu Muming, a researcher at the Center for Excellence and Innovation in Brain Science and Intelligent Technology of the Chinese Academy of Sciences, looked forward to the integration of artificial intelligence and brain science - general artificial intelligence (AGI) may soon approach humans in cognitive intelligence, but the realization of emotional and social intelligence still needs a long exploration. Cross border integration, where is the path for medical AI? The competition focus of medical AI is shifting from 'whether it can answer questions' to' whether it can make credible judgments based on medical evidence '. ”Ma Xiaowu, Executive Vice President of Easy Health Group, stated that the medical scene requires auxiliary decision-making capabilities that are traceable, interpretable, and verifiable. Wang Shirui, CEO of Future Doctor, a brand under the Medical Alliance Group, believes that there are underlying shortcomings in AI's embodied disposal ability and deep empathy ability that are difficult to overcome. Therefore, human-machine collaboration is an inevitable form of medical AGI. The innovation ecosystem is constantly being optimized. Looking at the Yangtze River Delta, the cluster effect of the future medical and pharmaceutical industry is becoming increasingly prominent, and the regional innovation highland is rising. The results of the 10th Future Medical Top 100 selection show that Beijing, Shanghai, and Suzhou rank among the top three in the list of innovative devices and intelligent manufacturing; In the list of innovative pharmaceuticals and biological products, Shanghai, Hangzhou, and Suzhou lead the way; In the list of innovative health services and industrial chain services, Beijing and Shanghai account for 62%, forming a dual core leading pattern. Among the three rankings, the new generation is growing rapidly. Among them, biopharmaceutical companies established after 2021 account for 22%, and innovative drug tracks such as AI pharmaceuticals, cell gene therapy, and nucleic acid drugs are bursting with entrepreneurial vitality. Innovation cannot be achieved without improving ecological support. The venue of the conference is Minhang District, Shanghai, which is a key carrier area of the city's biopharmaceutical industry. By 2025, the industry scale will reach 48.2 billion yuan, gathering more than 1000 biopharmaceutical enterprises. The district has established a policy system for the biopharmaceutical industry, covering the entire chain and providing precise track support, to help enterprises develop throughout the entire process from research and development, clinical practice to industrialization. In Shanghai, the improvement of the payment system is also safeguarding the landing of innovation. Diversified payments are the key to breaking through industry bottlenecks. "In the" Innovation "section of the forum, Qi Lei, Chief Financial Officer of Shanghai Magnesium Health Technology Co., Ltd., stated that the true realization of clinical value and market value of innovative drugs relies not only on the continuous breakthrough of cutting-edge pharmaceutical technology, but also on a sound and comprehensive multi-level medical payment guarantee system as a solid support. The globalization layout is accelerating, and China's innovation influence continues to expand. In the past year, innovative drug business development (BD) transactions have exceeded 130 billion US dollars, and China is striding from a major producer of generic drugs to a major exporter of innovative drugs. Li Datao, founder of the well-known future medical service platform Arterial Network, called on Chinese medical companies to actively define themselves, upgrade their understanding of "Made in China" to "Global Brands Born in China" by building a narrative system that combines executive IP and corporate brand, and thus gain a say in the global industry. China's integrated medical thinking and practice are influencing the concept and direction of world medical development. In recent years, the Chinese Anti Cancer Association has organized experts to create the "China Cancer Integrated Diagnosis and Treatment Guidelines" that are in line with the national conditions, which has increased the 5-year survival rate of cancer in China by 10% in ten years and benefited over 500000 patients annually. The guide has been translated into 16 languages and promoted globally through online conferences and other forms, covering hundreds of millions of people. In the future, we will transform integrated medical achievements into popular science and cultural products, and continue to export Chinese wisdom, "said Fan Daiming, Chairman of the China Anti Cancer Association, President of the Asian Oncology Society, and President of the World Integrated Oncology Association. (Looking into the New Era)